GTC and LFB Commence CD20 Monoclonal Antibody Development 25

Amgen Inks Collaboration and License Pact with Daiichi Sankyo 25

CMC Biopharmaceuticals Inks Agreement with Morphotek 26

CMC Biopharmaceuticals Inks Agreement with Biotest 26

Eli Lilly Collaborates with MacroGenics 26

Genentech Inks Global Licensing Agreement with Seattle Genetics 27

6. MAJOR PLAYERS 27

Amgen, Inc. (US) 27

BD Biosciences (US) 27

Biogen Idec Inc (US) 27

Biotest AG (Germany) 28

CMC ICOS Biologics, Inc. 28

Dendreon Corporation (US) 28

Elan Corporations Plc (Ireland) 28

Eli Lilly and Company (US) 28

Genentech, Inc. (US) 29

Human Genome Sciences, Inc. (US) 29

Immunomedics, Inc. (US) 29

Johnson & Johnson (US) 29

Centocor (US) 29

Ortho Biotech Products, L.P. (US) 30

Medarex, Inc. (US) 30

MedImmune, Inc. (US) 30

PDL BioPharma (US) 30

Schering-Plough Corporation (US) 31

Strategic Diagnostics Inc (US) 31

UCB Group (Belgium) 31

Wyeth Pharmaceuticals (US) 31

7. MARKET ANALYTICS 32

8. THE UNITED STATES 38

Therapeutic Monoclonal Antibodies Market - An Overview 38

New Heights for US Cancer Therapeutics 38

Competitive Landscape 39

Leading Products 39

9. CANADA 41

10. JAPAN 42

11. EUROPE 43

a. France 48

b. Germany 49

c. Italy 50

d. The United Kingdom 51

e. Rest of Europe 53

12. REST OF WORLD 54

Australia 54

Australia is All Set to Meet the Increasing Demand 54

India 54

SOURCE Reportlinker